Description Of Antihypertensive Drugs Use In Hypertensive Outpatients With Diabetes Mellitus At Panembahan Senopati Bantul Hospital
DOI:
https://doi.org/10.31316/astro.v3i1.6143Abstract
Hypertension (HT) is still a health problem in the world, including in Indonesia. Hypertension in patients with type 2 diabetes mellitus (T2DM) will have an impact on worsening conditions and multi-complications, including macrovascular, microvascular, and insulin resistance complications. This can be prevented by providing appropriate and rational therapy so that the effectiveness of therapy is achieved and avoid worsening conditions and complications. This study aims to determine the pattern of antihypertensive drug use in HT patients with comorbid T2DM in the outpatient installation of Panembahan Senopati Hospital, Bantul for the period of August 2023. The study was designed with a descriptive non-experimental method, cross-sectional with a retrospective approach. The source of research data is secondary data derived from medical records of HT patients with T2DM for the period of August 2023 with data collection by purposive sampling. A total of 157 HT patients met the inclusion criteria in this study with the prevalence of women (n = 106; 67.50%) and men (n = 51; 32.50%), most ages in the 55-65 year range (n = 57; 36.30%). A total of 66 patients (42.10%) received monotherapy, while 91 (57.90) patients received polytherapy. Candesartan (n=80; 27.68%) and Amlodipine (n=78; 26.99%) monotherapy with oral administration were the most common treatment options in this study. Overall, the most widely used drug classes were Angiotensin Receptor Blockers (ARB) (41.18%), Calcium Channel Blockers (CCB) (32.5%), and Diuretics (14.1%). While the most common combination of drug groups is ARB + CCB (24.8%). This study concluded that the use of drugs mainly was polytherapy and in general the use of antihypertensive drugs consisted of 7 classes of drugs namely Angiotensin Receptor Blockers, Calcium Channel Blockers, Diuretics, ẞ- blockers, Centrally-acting Agents, ACE-Inhibitors, Vasodilators
Downloads
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2024 Rahmat A Hi Wahid, Anis Febri Nilansari, Fitri Andriani Fatimah
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal allow the authors to hold the copyright without restrictions and allow the authors to retain publishing rights without restrictions.
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).